Is Adaptimmune Therapeutics Stock a Good Investment?
Adaptimmune Therapeutics Investment Advice | ADAP |
- Examine Adaptimmune Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Adaptimmune Therapeutics' leadership team and their track record. Good management can help Adaptimmune Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Adaptimmune Therapeutics' business and its evolving consumer preferences.
- Compare Adaptimmune Therapeutics' performance and market position to its competitors. Analyze how Adaptimmune Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Adaptimmune Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Adaptimmune Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Adaptimmune Therapeutics Plc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Adaptimmune Therapeutics Plc is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Adaptimmune Therapeutics Stock
Researching Adaptimmune Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 60.0% of the company shares are held by institutions such as insurance companies. The book value of Adaptimmune Therapeutics was presently reported as 0.17. The company has Price/Earnings To Growth (PEG) ratio of 0.11. Adaptimmune Therapeutics recorded a loss per share of 0.17. The entity last dividend was issued on the 30th of March 2018.
To determine if Adaptimmune Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Adaptimmune Therapeutics' research are outlined below:
| Adaptimmune Therapeutics generated a negative expected return over the last 90 days | |
| Adaptimmune Therapeutics has some characteristics of a very speculative penny stock | |
| Adaptimmune Therapeutics has high historical volatility and very poor performance | |
| Adaptimmune Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 60.28 M. Net Loss for the year was (113.87 M) with loss before overhead, payroll, taxes, and interest of (100.58 M). | |
| Adaptimmune Therapeutics Plc currently holds about 199.67 M in cash with (140.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 60.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Europes TCR immunotherapy licensing deals surge 123 percent above US in 2024 |
Adaptimmune Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Adaptimmune Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Adaptimmune Therapeutics Plc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adaptimmune Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Adaptimmune Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Adaptimmune Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-03-17 | 2015-12-31 | -0.14 | -0.16 | -0.02 | 14 | ||
2022-08-04 | 2022-06-30 | -0.25 | -0.28 | -0.03 | 12 | ||
2017-03-13 | 2016-12-31 | -0.27 | -0.24 | 0.03 | 11 | ||
2016-05-12 | 2016-03-31 | -0.19 | -0.22 | -0.03 | 15 | ||
2021-11-04 | 2021-09-30 | -0.26 | -0.3 | -0.04 | 15 | ||
2020-02-27 | 2019-12-31 | -0.34 | -0.3 | 0.04 | 11 | ||
2019-02-27 | 2018-12-31 | -0.32 | -0.36 | -0.04 | 12 | ||
2017-05-10 | 2017-03-31 | -0.26 | -0.3 | -0.04 | 15 |
Know Adaptimmune Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Adaptimmune Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Adaptimmune Therapeutics Plc backward and forwards among themselves. Adaptimmune Therapeutics' institutional investor refers to the entity that pools money to purchase Adaptimmune Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 1.7 M | Jpmorgan Chase & Co | 2024-06-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 881.7 K | Millennium Management Llc | 2024-06-30 | 779.6 K | Redmile Group, Llc | 2024-09-30 | 715.6 K | Rathbone Brothers Plc | 2024-06-30 | 432.8 K | State Street Corp | 2024-06-30 | 390.9 K | Dafna Capital Management Llc | 2024-09-30 | 341.1 K | Key Client Fiduciary Advisors, Llc | 2024-09-30 | 255.4 K | Matrix Capital Management Company, Llc | 2024-06-30 | 39 M | Ecor1 Capital, Llc | 2024-09-30 | 27.4 M |
Adaptimmune Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 169.29 M.Market Cap |
|
Adaptimmune Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (2.88) | (2.74) |
Determining Adaptimmune Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Adaptimmune Therapeutics is a good buy. For example, gross profit margin measures Adaptimmune Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Adaptimmune Therapeutics' profitability and make more informed investment decisions.
Evaluate Adaptimmune Therapeutics' management efficiency
Adaptimmune Therapeutics has return on total asset (ROA) of (0.1584) % which means that it has lost $0.1584 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. Adaptimmune Therapeutics' management efficiency ratios could be used to measure how well Adaptimmune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/24/2024, Return On Tangible Assets is likely to drop to -0.42. In addition to that, Return On Capital Employed is likely to drop to -0.69. As of 11/24/2024, Non Current Liabilities Total is likely to grow to about 178.8 M, while Total Current Liabilities is likely to drop slightly above 44.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.20 | 0.19 | |
| Tangible Book Value Per Share | 0.19 | 0.19 | |
| Enterprise Value Over EBITDA | (0.32) | (0.33) | |
| Price Book Value Ratio | 4.04 | 4.24 | |
| Enterprise Value Multiple | (0.32) | (0.33) | |
| Price Fair Value | 4.04 | 4.24 | |
| Enterprise Value | 40.7 M | 38.7 M |
Evaluating the management effectiveness of Adaptimmune Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Adaptimmune Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 2.247 |
Basic technical analysis of Adaptimmune Stock
As of the 24th of November, Adaptimmune Therapeutics shows the mean deviation of 3.18, and Risk Adjusted Performance of (0.11). Adaptimmune Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Adaptimmune Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptimmune Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptimmune Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptimmune Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adaptimmune Therapeutics' Outstanding Corporate Bonds
Adaptimmune Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Adaptimmune Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Adaptimmune bonds can be classified according to their maturity, which is the date when Adaptimmune Therapeutics Plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ADAPTHEALTH LLC 6125 Corp BondUS00653VAA98 | View | |
| AdaptHealth LLC 4625 Corp BondUS00653VAC54 | View | |
| US00653VAE11 Corp BondUS00653VAE11 | View |
Understand Adaptimmune Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Adaptimmune Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.51) | |||
| Mean Deviation | 3.18 | |||
| Coefficient Of Variation | (630.84) | |||
| Standard Deviation | 4.72 | |||
| Variance | 22.27 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (1.50) | |||
| Treynor Ratio | (0.52) | |||
| Maximum Drawdown | 33.29 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 5.56 | |||
| Skewness | (1.13) | |||
| Kurtosis | 7.8 |
| Risk Adjusted Performance | (0.11) | |||
| Market Risk Adjusted Performance | (0.51) | |||
| Mean Deviation | 3.18 | |||
| Coefficient Of Variation | (630.84) | |||
| Standard Deviation | 4.72 | |||
| Variance | 22.27 | |||
| Information Ratio | (0.19) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (1.50) | |||
| Treynor Ratio | (0.52) | |||
| Maximum Drawdown | 33.29 | |||
| Value At Risk | (6.00) | |||
| Potential Upside | 5.56 | |||
| Skewness | (1.13) | |||
| Kurtosis | 7.8 |
Consider Adaptimmune Therapeutics' intraday indicators
Adaptimmune Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Adaptimmune Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Adaptimmune Therapeutics time-series forecasting models is one of many Adaptimmune Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adaptimmune Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Adaptimmune Stock media impact
Far too much social signal, news, headlines, and media speculation about Adaptimmune Therapeutics that are available to investors today. That information is available publicly through Adaptimmune media outlets and privately through word of mouth or via Adaptimmune internal channels. However, regardless of the origin, that massive amount of Adaptimmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Adaptimmune Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Adaptimmune Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Adaptimmune Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Adaptimmune Therapeutics alpha.
Adaptimmune Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Adaptimmune Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Adaptimmune Therapeutics Corporate Management
| Kerry Sharp | Senior Council | Profile | |
| Dennis Williams | Senior Development | Profile | |
| Sbastien Desprez | VP Affairs | Profile | |
| Dana Lynch | Senior Communications | Profile | |
| Helen MBA | CoFounder Officer | Profile | |
| Bertrand Esq | Chief Officer | Profile |
Already Invested in Adaptimmune Therapeutics Plc?
The danger of trading Adaptimmune Therapeutics Plc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adaptimmune Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adaptimmune Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adaptimmune Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Adaptimmune Stock Analysis
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.